Recombinant Brain Natriuretic Peptide for the Prevention of Contrast-Induced Nephropathy in Patients with Chronic Kidney Disease Undergoing Nonemergent Percutaneous Coronary Intervention or Coronary Angiography: A Randomized Controlled Trial

Abstract EN

The role of brain natriuretic peptide (BNP) in the prevention of contrast-induced nephropathy (CIN) is unknown.

This study aimed to investigate BNP’s effect on CIN in chronic kidney disease (CKD) patients undergoing elective percutaneous coronary intervention (PCI) or coronary angiography (CAG).

The patients were randomized to BNP (0.005 μg/kg/min before contrast media (CM) exposure and saline hydration, n=106) or saline hydration alone (n=103).

Cystatin C, serum creatinine (SCr) levels, and estimated glomerular filtration rates (eGFR) were assessed at several time points.

The primary endpoint was CIN incidence; secondary endpoint included changes in cystatin C, SCr, and eGFR.

CIN incidence was significantly lower in the BNP group compared to controls (6.6% versus 16.5%, P=0.025).

In addition, a more significant deterioration of eGFR, cystatin C, and SCr from 48 h to 1 week (P<0.05) was observed in controls compared to the BNP group.

Although eGFR gradually deteriorated in both groups, a faster recovery was achieved in the BNP group.

Multivariate logistic regression revealed that using >100 mL of CM (odds ratio: 4.36, P=0.004) and BNP administration (odds ratio: 0.21, P=0.006) were independently associated with CIN.

Combined with hydration, exogenous BNP administration before CM effectively decreases CIN incidence in CKD patients.